Tags

Type your tag names separated by a space and hit enter

α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy.
Angiology. 2012 Feb; 63(2):81-3.A

Abstract

Both oral and intravenous administration of alpha-lipoic acid (ALA) has been investigated as add-on treatment for diabetic peripheral neuropathy. The recent Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial has shown that 4-year oral ALA administration is of some value in achieving a clinically meaningful improvement and a slight delay in the progression of neuropathic deficits among patients with mild/moderate diabetic peripheral neuropathy. Despite these promising results, important questions remain to be answered, mainly appropriate patient selection and optimal treatment duration. Moreover, a cost-benefit analysis would be useful.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Editorial

Language

eng

PubMed ID

22253286

Citation

Papanas, N, and E Maltezos. "Α-Lipoic Acid, Diabetic Neuropathy, and Nathan's Prophecy." Angiology, vol. 63, no. 2, 2012, pp. 81-3.
Papanas N, Maltezos E. Α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy. Angiology. 2012;63(2):81-3.
Papanas, N., & Maltezos, E. (2012). Α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy. Angiology, 63(2), 81-3. https://doi.org/10.1177/0003319711421165
Papanas N, Maltezos E. Α-Lipoic Acid, Diabetic Neuropathy, and Nathan's Prophecy. Angiology. 2012;63(2):81-3. PubMed PMID: 22253286.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy. AU - Papanas,N, AU - Maltezos,E, PY - 2012/1/19/entrez PY - 2012/1/19/pubmed PY - 2012/3/7/medline SP - 81 EP - 3 JF - Angiology JO - Angiology VL - 63 IS - 2 N2 - Both oral and intravenous administration of alpha-lipoic acid (ALA) has been investigated as add-on treatment for diabetic peripheral neuropathy. The recent Neurological Assessment of Thioctic Acid in Diabetic Neuropathy (NATHAN) 1 trial has shown that 4-year oral ALA administration is of some value in achieving a clinically meaningful improvement and a slight delay in the progression of neuropathic deficits among patients with mild/moderate diabetic peripheral neuropathy. Despite these promising results, important questions remain to be answered, mainly appropriate patient selection and optimal treatment duration. Moreover, a cost-benefit analysis would be useful. SN - 1940-1574 UR - https://www.unboundmedicine.com/medline/citation/22253286/α_Lipoic_acid_diabetic_neuropathy_and_Nathan's_prophecy_ L2 - http://journals.sagepub.com/doi/full/10.1177/0003319711421165?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -